Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (154)	11/7/2003 1:37:19 PM
From: tuck	Read Replies (1) \| Respond to of 566

From Briefing.com: >>9:14AM Rigel Pharms started with an Outperform at CSFB; target $26 (RIGL) 14.89: CSFB initiates coverage with an Outperform rating and $26 target; firm believes that the co's hepatitis C small molecule program alone is worth more than $14/share, the co will have two potential $1 bln drug candidates from novel drug classes in the clinic in 2003, and has a drug discovery platform that could yield multiple cancer product candidates entering the clinic in 2005.<< Cheers, Tuck